Search

Search Constraints

You searched for: Author/Creator Shou, Yaping

Search Results

3. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Issue 11 (November 2021)

9. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. Issue 7 (2nd June 2020)